Pharmacokinetics of methylene blue dye for lymphatic mapping in breast cancerimplications for use in pregnancy

Sandhya Pruthi, Caroline Haakenson, Brian C. Brost, Kanesha Bryant, Joel M Reid, Ravinder Jit Singh, Brian Netzel, Judy C Boughey, Amy C Degnim

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Although blue dye is routinely used for lymphatic mapping, it is not used for lymphatic mapping in pregnancy-associated breast cancer, because of concern of fetal risk. Methods: To investigate the safety of blue dye for lymphatic mapping in pregnant women, the pharmacokinetics of methylene blue dye were examined in 10 nonpregnant women, and the results were extrapolated to estimate maximal fetal exposure to the dye. Results: Plasma and urine measurements indicated that the dye quickly distributed from the breast injection site to the circulation, with 32% of the total dose excreted in urine within 48 hours. Combined with existing data on organ distribution of methylene blue, the estimated maximal dose to the fetus is 0.25 mg (5% of the administered dose), likely further reduced by other physiologic factors related to pregnancy. Conclusions: The analysis suggests that methylene blue dye can be used for lymphatic mapping in pregnancy-associated breast cancer with minimal fetal risk.

Original languageEnglish (US)
Pages (from-to)70-75
Number of pages6
JournalAmerican Journal of Surgery
Volume201
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Methylene Blue
Breast
Coloring Agents
Pharmacokinetics
Pregnancy
Urine
Breast Neoplasms
Pregnant Women
Fetus
Safety
Injections

Keywords

  • Methylene blue
  • Pharmacokinetics
  • Sentinel lymph node biopsy

ASJC Scopus subject areas

  • Surgery

Cite this

Pharmacokinetics of methylene blue dye for lymphatic mapping in breast cancerimplications for use in pregnancy. / Pruthi, Sandhya; Haakenson, Caroline; Brost, Brian C.; Bryant, Kanesha; Reid, Joel M; Singh, Ravinder Jit; Netzel, Brian; Boughey, Judy C; Degnim, Amy C.

In: American Journal of Surgery, Vol. 201, No. 1, 01.2011, p. 70-75.

Research output: Contribution to journalArticle

@article{4532026cb354418a95dfbc265612dcdd,
title = "Pharmacokinetics of methylene blue dye for lymphatic mapping in breast cancerimplications for use in pregnancy",
abstract = "Background: Although blue dye is routinely used for lymphatic mapping, it is not used for lymphatic mapping in pregnancy-associated breast cancer, because of concern of fetal risk. Methods: To investigate the safety of blue dye for lymphatic mapping in pregnant women, the pharmacokinetics of methylene blue dye were examined in 10 nonpregnant women, and the results were extrapolated to estimate maximal fetal exposure to the dye. Results: Plasma and urine measurements indicated that the dye quickly distributed from the breast injection site to the circulation, with 32{\%} of the total dose excreted in urine within 48 hours. Combined with existing data on organ distribution of methylene blue, the estimated maximal dose to the fetus is 0.25 mg (5{\%} of the administered dose), likely further reduced by other physiologic factors related to pregnancy. Conclusions: The analysis suggests that methylene blue dye can be used for lymphatic mapping in pregnancy-associated breast cancer with minimal fetal risk.",
keywords = "Methylene blue, Pharmacokinetics, Sentinel lymph node biopsy",
author = "Sandhya Pruthi and Caroline Haakenson and Brost, {Brian C.} and Kanesha Bryant and Reid, {Joel M} and Singh, {Ravinder Jit} and Brian Netzel and Boughey, {Judy C} and Degnim, {Amy C}",
year = "2011",
month = "1",
doi = "10.1016/j.amjsurg.2009.03.013",
language = "English (US)",
volume = "201",
pages = "70--75",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetics of methylene blue dye for lymphatic mapping in breast cancerimplications for use in pregnancy

AU - Pruthi, Sandhya

AU - Haakenson, Caroline

AU - Brost, Brian C.

AU - Bryant, Kanesha

AU - Reid, Joel M

AU - Singh, Ravinder Jit

AU - Netzel, Brian

AU - Boughey, Judy C

AU - Degnim, Amy C

PY - 2011/1

Y1 - 2011/1

N2 - Background: Although blue dye is routinely used for lymphatic mapping, it is not used for lymphatic mapping in pregnancy-associated breast cancer, because of concern of fetal risk. Methods: To investigate the safety of blue dye for lymphatic mapping in pregnant women, the pharmacokinetics of methylene blue dye were examined in 10 nonpregnant women, and the results were extrapolated to estimate maximal fetal exposure to the dye. Results: Plasma and urine measurements indicated that the dye quickly distributed from the breast injection site to the circulation, with 32% of the total dose excreted in urine within 48 hours. Combined with existing data on organ distribution of methylene blue, the estimated maximal dose to the fetus is 0.25 mg (5% of the administered dose), likely further reduced by other physiologic factors related to pregnancy. Conclusions: The analysis suggests that methylene blue dye can be used for lymphatic mapping in pregnancy-associated breast cancer with minimal fetal risk.

AB - Background: Although blue dye is routinely used for lymphatic mapping, it is not used for lymphatic mapping in pregnancy-associated breast cancer, because of concern of fetal risk. Methods: To investigate the safety of blue dye for lymphatic mapping in pregnant women, the pharmacokinetics of methylene blue dye were examined in 10 nonpregnant women, and the results were extrapolated to estimate maximal fetal exposure to the dye. Results: Plasma and urine measurements indicated that the dye quickly distributed from the breast injection site to the circulation, with 32% of the total dose excreted in urine within 48 hours. Combined with existing data on organ distribution of methylene blue, the estimated maximal dose to the fetus is 0.25 mg (5% of the administered dose), likely further reduced by other physiologic factors related to pregnancy. Conclusions: The analysis suggests that methylene blue dye can be used for lymphatic mapping in pregnancy-associated breast cancer with minimal fetal risk.

KW - Methylene blue

KW - Pharmacokinetics

KW - Sentinel lymph node biopsy

UR - http://www.scopus.com/inward/record.url?scp=78650347183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650347183&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2009.03.013

DO - 10.1016/j.amjsurg.2009.03.013

M3 - Article

VL - 201

SP - 70

EP - 75

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 1

ER -